Abbott Laboratories Stock News

Abbott (NYSE: ABT) will report its Q1 2024 results on Wednesday, April 17. We expect the company to post revenue of $9.9 billion and earnings of $0.95 on a per share and adjusted basis, aligning with

Several top-rated Zacks stocks are standing out before their first-quarter earnings report next week and here are three to consider.

Abbott (ABT) is likely to have progressed with its initiative to commercialize several biosimilars in emerging markets.

Evaluate the expected performance of Abbott (ABT) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for

With rising concerns in the market potentially forcing a strategic shift, investors may want to consider healthcare stocks. No matter what happens, people need access to health-related products and se

The latest trading day saw Abbott (ABT) settling at $112.44, representing a +1.74% change from its previous close.

Investors looking for stocks in the Medical - Products sector might want to consider either Haemonetics (HAE) or Abbott (ABT). But which of these two stocks is more attractive to value investors?

Abbott's (ABT) core laboratory diagnostics business is gaining strength on the continued success of the Alinity suite of diagnostics instruments, along with a broad test menu offering.

Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Abbott (ABT) receives FDA nod for TriClip, a first-of-its-kind device to repair a leaky tricuspid heart valve.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe

Abbott's (ABT) i-STAT Alinity instrument uses whole blood to help assess patients with a suspected mild traumatic brain injury or concussion.

Abbott Laboratories said on Tuesday the U.S. FDA has approved its heart valve repair device designed for patients at risk of complications or death during open-heart surgeries.

Abbott (ABT) concluded the recent trading session at $112.09, signifying a -1.38% move from its prior day's close.

As the number of grey-haired people rises worldwide, investors need to notice the strong-buy  healthcare stocks. The need for healthcare will grow as the number of people aged 60 years and older dou